期刊
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
卷 30, 期 6, 页码 563-569出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jpainsymman.2005.05.018
关键词
long-acting octreotide; ovarian cancer; bowel obstruction
Symptoms of malignant bowel obstruction in patients with recurrent ovarian cancer lead to a poor quality of life. Sandostatin LAR (R) Depot (LAR) (Novartis Pharmaceuticals Corp., East Hanover, NJ) is an intramuscular, monthly administered, long-acting form of octreolide. LARs safety and utility were evaluated in a pilot study enrolling 15 advanced ovarian cancer patients with bowel dysfunction. Once safety with subcutaneous (SQ) octreotide was assessed, patients were given 30 mg LAR on Day 1 and octreotide SQ for 2 weeks. Of 13 evaluable patients, three patients had a major response to LAR treatment with reduction in bowel obstruction symptoms, two had a minor response, four had no response, and four had progressive symptoms. Three patients remained on LAR for more than 9 months. No significant toxicities were attributable to octreolide or LAR. Because three patients received nine or more monthly injections of LAR, possible direct antitumor effects Of LAR or synergy with chemotherapy needs to be explored.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据